Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 2:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 547 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Thromboses, Venous Clear all
Terminated No phase listed Observational Accepts healthy volunteers Results available

Sickle Cell Trait and the Risk of Venous Thromboembolism

NCT01148940
View directory record Official record
Conditions
Thrombosis
Interventions
Not listed
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Sep 30, 2026, 2:01 AM EDT
Completed Phase 3 Interventional

Dalteparin Low Molecular Weight Heparin for Primary Prophylaxis of Venous Thromboembolism in Brain Tumour Patients

NCT00135876
View directory record Official record
Conditions
Venous Thromboembolism, Brain Tumors
Interventions
dalteparin
Drug
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Other
Eligibility
18 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
3
States / cities
Evanston, Illinois • Detroit, Michigan • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2007 · Synced Sep 30, 2026, 2:01 AM EDT
Completed Phase 3 Interventional Results available

Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.

NCT00056550
View directory record Official record
Conditions
Antithrombin Deficiency, Congenital
Interventions
Recombinant Human Antithrombin (rhAT)
Biological
Lead sponsor
rEVO Biologics
Industry
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
2
States / cities
Marietta, Georgia • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2012 · Synced Sep 30, 2026, 2:01 AM EDT
Completed Not applicable Interventional Results available

Once Daily Enoxaparin for Outpatient Treatment of Acute DVT and/or Pulmonary Embolism

NCT00413374
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Sep 30, 2026, 2:01 AM EDT
Not yet recruiting Phase 3 Interventional

Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP).

NCT06628778
View directory record Official record
Conditions
Venous Thromboembolism (VTE)
Interventions
Enoxaparin
Drug
Lead sponsor
Johns Hopkins All Children's Hospital
Other
Eligibility
12 Years to 18 Years
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2035
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Sep 30, 2026, 2:01 AM EDT
Completed Phase 2 Interventional Results available

Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients

NCT03251963
View directory record Official record
Conditions
Venous Thromboembolism, Deep Venous Thrombosis, Surgery
Interventions
Fixed Dose Enoxaparin, Variable Dose Enoxaparin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Sep 30, 2026, 2:01 AM EDT
Completed Phase 2 Interventional Results available

Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT03739593
View directory record Official record
Conditions
Macular Edema
Interventions
AR-1105-CF1, AR-1105-CF2
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Phoenix, Arizona • Beverly Hills, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2022 · Synced Sep 30, 2026, 2:01 AM EDT
Completed Phase 2 Interventional Results available

Odiparcil For The Prevention Of Venous Thromboembolism

NCT00244725
View directory record Official record
Conditions
Deep Vein Thrombosis, Fibrillation, Atrial, Venous Thromboembolism, Pulmonary Embolism
Interventions
Odiparcil, Warfarin, Coumadin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
35 Years and older
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
46
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Sep 30, 2026, 2:01 AM EDT
Completed Not applicable Interventional

The ATLANTIS Trial

NCT02553720
View directory record Official record
Conditions
Chronic Venous Hypertension Due to Deep Vein Thrombosis, Venous Reflux
Interventions
exercise in water, aquatic activity plus conventional management
Other
Lead sponsor
Arizona Cardiovascular Consultants
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Sep 30, 2026, 2:01 AM EDT
Terminated Phase 2 Interventional

Tinzaparin for Primary Treatment and Extended Secondary Prophylaxis of Venous Thromboembolism in Patients With Cancer

NCT00981903
View directory record Official record
Conditions
Venous Thromboembolism, Cancer
Interventions
Tinzaparin sodium
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Sep 30, 2026, 2:01 AM EDT
Completed No phase listed Observational

Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort

NCT04979780
View directory record Official record
Conditions
Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients
Interventions
Rivaroxaban (Xarelto, BAY59-7939), Low molecular weight heparin (LMWH), Direct Oral Anticoagulants (DOAC)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,708 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Multiple Locations, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 31, 2024 · Synced Sep 30, 2026, 2:01 AM EDT
Completed Phase 3 Interventional Results available

Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

NCT00986154
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism, Venous Thrombosis
Interventions
edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
8,292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
82
States / cities
Mobile, Alabama • Montgomery, Alabama • Phoenix, Arizona + 71 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 30, 2026, 2:01 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Venous Thrombosis Prevention and Sleep Quality: A Comparison of the Kendall and the Recovery Health MAC Systems

NCT06042686
View directory record Official record
Conditions
Deep Venous Thrombosis of Deep Femoral Vein
Interventions
RF Health MAC Device
Device
Lead sponsor
University of Massachusetts, Amherst
Other
Eligibility
50 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Amherst, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Sep 30, 2026, 2:01 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Catheters

NCT00322270
View directory record Official record
Conditions
Thrombosis, Venous Thrombosis, Catheter Occlusion
Interventions
Alfimeprase
Drug
Lead sponsor
ARCA Biopharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
18
States / cities
Casa Grande, Arizona • Soquel, California • Boynton Beach, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2008 · Synced Sep 30, 2026, 2:01 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Dalteparin Prophylaxis in High-Risk Ambulatory Cancer Patients

NCT00876915
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolism
Interventions
dalteparin injection
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
6
States / cities
Sacramento, California • Buffalo, New York • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Sep 30, 2026, 2:01 AM EDT
Completed No phase listed Observational

Replication of the RECORD1 Anticoagulant Trial in Healthcare Claims Data

NCT05083455
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolus
Interventions
Rivaroxaban, Enoxaparin
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
89,215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 30, 2026, 2:01 AM EDT
Completed No phase listed Observational Results available

A Study to Compare Health Care Costs Between Apixaban and Low Molecular Weight Heparin in Patients With Venous Thromboembolism and Cancer

NCT05643885
View directory record Official record
Conditions
Thromboembolism
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
7,304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Sep 30, 2026, 2:01 AM EDT
Completed Phase 2 Interventional Results available

Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma

NCT03339349
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolus
Interventions
Enoxaparin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 30, 2026, 2:01 AM EDT
Terminated Phase 1 Interventional Results available

PET Fibrin Imaging of DVT and PE

NCT04022915
View directory record Official record
Conditions
Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
Interventions
64Cu-FBP8, PET-CT imaging
Drug · Diagnostic Test
Lead sponsor
Peter Caravan
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 30, 2026, 2:01 AM EDT
Terminated No phase listed Observational

A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness

NCT05819112
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
40 Years and older
Enrollment
14,799 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 30, 2026, 2:01 AM EDT
Completed Phase 3 Interventional Results available

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

NCT02064439
View directory record Official record
Conditions
Pulmonary Embolism, Thromboembolism, Thrombosis, Venous Thrombosis, Venous Thromboembolism
Interventions
BAY 59-7939, ASA
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
3,365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Beverly Hills, California • La Jolla, California • Ventura, California + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Sep 30, 2026, 2:01 AM EDT
Withdrawn No phase listed Observational

Multicenter Registry for Comparative Effectiveness Analysis of Venous Thromboembolism in Trauma Patients

NCT01890044
View directory record Official record
Conditions
Venous Thromboembolism, Pulmonary Embolus, Deep Vein Thrombosis
Interventions
Not listed
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Sep 30, 2026, 2:01 AM EDT
Completed No phase listed Observational

Study of Peripherally Inserted Venous Catheters in Cystic Fibrosis Patients

NCT03674216
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Jonathan B. Zuckerman
Other
Eligibility
6 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Sep 30, 2026, 2:01 AM EDT
Active, not recruiting No phase listed Observational

Post Market Registry Study of the Philips QuickClear Mechanical Thrombectomy System

NCT05928221
View directory record Official record
Conditions
Acute Deep Venous Thrombosis of Ileofemoral Vein
Interventions
Thrombectomy
Device
Lead sponsor
Paul J. Gagne
Other
Eligibility
18 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Darien, Connecticut • Hyannis, Massachusetts • Leominster, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Sep 30, 2026, 2:01 AM EDT